JP2020518604A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518604A5
JP2020518604A5 JP2019560115A JP2019560115A JP2020518604A5 JP 2020518604 A5 JP2020518604 A5 JP 2020518604A5 JP 2019560115 A JP2019560115 A JP 2019560115A JP 2019560115 A JP2019560115 A JP 2019560115A JP 2020518604 A5 JP2020518604 A5 JP 2020518604A5
Authority
JP
Japan
Prior art keywords
seq
immunoglobulin
patient
ige
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019560115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518604A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/053106 external-priority patent/WO2018203289A1/en
Publication of JP2020518604A publication Critical patent/JP2020518604A/ja
Publication of JP2020518604A5 publication Critical patent/JP2020518604A5/ja
Pending legal-status Critical Current

Links

JP2019560115A 2017-05-05 2018-05-04 Ｉｌ−１７アンタゴニストを使用して喘息を選択的に治療する方法 Pending JP2020518604A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762501806P 2017-05-05 2017-05-05
US62/501,806 2017-05-05
PCT/IB2018/053106 WO2018203289A1 (en) 2017-05-05 2018-05-04 Methods of selectively treating asthma using il-17 antagonists

Publications (2)

Publication Number Publication Date
JP2020518604A JP2020518604A (ja) 2020-06-25
JP2020518604A5 true JP2020518604A5 (enExample) 2020-09-24

Family

ID=62245372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019560115A Pending JP2020518604A (ja) 2017-05-05 2018-05-04 Ｉｌ−１７アンタゴニストを使用して喘息を選択的に治療する方法

Country Status (13)

Country Link
US (1) US10676522B2 (enExample)
EP (1) EP3619536A1 (enExample)
JP (1) JP2020518604A (enExample)
KR (1) KR20190142398A (enExample)
CN (1) CN110582702A (enExample)
AU (1) AU2018263159A1 (enExample)
BR (1) BR112019023141A2 (enExample)
CA (1) CA3062179A1 (enExample)
CL (1) CL2019003161A1 (enExample)
MX (1) MX2019013160A (enExample)
RU (1) RU2019139387A (enExample)
TW (1) TW201842933A (enExample)
WO (1) WO2018203289A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689907A1 (en) * 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
WO2021211430A1 (en) * 2020-04-17 2021-10-21 Eli Lilly And Company Treatment of respiratory disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308324D0 (en) 2003-04-10 2003-05-14 Piezoptic Ltd A chemical sensing device
CN1898564A (zh) * 2003-12-24 2007-01-17 惠氏公司 治疗哮喘的方法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JP6161233B2 (ja) 2008-03-31 2017-07-12 ジェネンテック， インコーポレイテッド 喘息の治療及び診断のための組成物及び方法
KR101318549B1 (ko) 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
MX371052B (es) 2013-02-08 2020-01-14 Novartis Ag Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios.
BR112016008694A2 (pt) * 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
WO2015191783A2 (en) * 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
US11278618B2 (en) * 2014-09-10 2022-03-22 Novartis Ag Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
GB201508832D0 (en) 2015-05-22 2015-07-01 Novartis Ag A method for detecting an analyte

Similar Documents

Publication Publication Date Title
US12044681B2 (en) Protein signatures for distinguishing between bacterial and viral infections
Laing et al. A dynamic COVID-19 immune signature includes associations with poor prognosis
US20240369552A1 (en) Early diagnosis of infections
EP3475702B3 (en) Measuring trail by lateral flow immunoassay
Yu et al. mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants
EP4033248B1 (en) System and method for analysis of mx1 and crp in blood
JP2016535283A (ja) アルツハイマー病および他の神経変性障害のためのバイオマーカーおよび診断方法
JP2022160422A (ja) エキソソームの亜集団の定量および神経変性障害の診断
Jalali et al. Aptamer based diagnosis of crimean-congo hemorrhagic fever from clinical specimens
CN113791212B (zh) 新型冠状病毒中和抗体磁珠荧光检测试剂盒及其检测方法
Price et al. Detection of tissue factor–positive extracellular vesicles using the ExoView R100 system
JP2024534348A5 (enExample)
JP2005510696A5 (enExample)
JP2007502837A5 (enExample)
JP2019526231A (ja) 二本鎖核酸信号プローブおよびこれを用いた標的分子の検出方法
JP2018506020A (ja) 核酸増幅と組合せたイムノアッセイによる固体支持体上の被検体検出
CN103243101A (zh) 一组特异性识别金黄色葡萄球菌肠毒素c1的核酸适配体
Andre et al. Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients
Kim et al. A one-step immunoassay based on switching peptides for diagnosis of porcine epidemic diarrhea virus (PEDV) using screened Fv-antibodies
WO2023034933A1 (en) Methods and systems for assessing adaptive immunity to coronavirus
RU2019139387A (ru) Способы селективного лечения астмы с использованием антагонистов il-17
JP2019032317A5 (enExample)
Grace et al. Latex agglutination test for rapid on-site serodiagnosis of Japanese encephalitis in pigs using recombinant NS1 antigen
CN103045600B (zh) 结核患者血清IgG抗体适配子及其制备方法
CA2870320C (en) Rapid test for cellular fibronectin